免疫检查点抑制剂的不良反应及处理原则

发布时间：2018-01-01 19:44

本文关键词：免疫检查点抑制剂的不良反应及处理原则　出处：《中国新药杂志》2017年07期 　论文类型：期刊论文

【摘要】：目的:探讨免疫检查点抑制剂(immune checkpoint blockade,ICB)的不良反应及其处理原则。方法:采取文献回顾的方法对ICB出现的不良反应及处理原则进行归纳总结。结果:ICB的不良反应主要是其特有的免疫相关不良反应(immune-related adverse events,ir AEs),可累及全身多个脏器和系统,可发生在治疗全过程甚至治疗结束后,其处理原则包括预防、评估、检查、治疗和监测,早期的识别和检测是管理的关键。结论:虽然大多数ir AEs通过延迟给药及皮质内固醇激素治疗可以控制并且可逆,但有些ICB的不良反应可带来严重后果,因此临床医生应实行患者教育,早期识别并及时处理,以提高肿瘤免疫治疗的安全性。
[Abstract]:Objective: To investigate the immune checkpoint inhibitors (Immune checkpoint, blockade, ICB) the adverse reactions and treatment principles. Methods: summary of adverse reactions and treatment principles adopted the method of literature review of ICB. Results: the main adverse reaction of ICB is its unique immune related adverse reactions (immune-related adverse events, IR AEs), the body can affect multiple organs and systems, can occur in the whole treatment process even after the end of treatment, the treatment principles including prevention, assessment, examination, treatment and monitoring, identification and early detection is the key to management. Conclusion: Although the majority of IR AEs by delaying the administration of corticosteroids and hormone therapy can control and reversible, but the adverse reaction of some ICB can have serious consequences, so clinicians should implement the patient education, early recognition and timely treatment, in order to improve the safety of tumor immunotherapy .

【作者单位】：国家癌症中心/中国医学科学院北京协和医学院肿瘤医院;
【分类号】：R392-33
【正文快照】： 近年来,免疫治疗已成为肿瘤治疗的第四大治疗模式,尤其是免疫检查点抑制剂(immune check-point blockade,ICB)的研究取得了重大突破,如抗CTLA-4抗体和抗PD-1/PD-L1抗体,其中ipilimum-ab,nivolumab,pembrolizumab,atezolizumab已经获得FDA批准,证实在黑色素瘤、非小细胞肺癌、

【相似文献】